Maini Sir Ravinder
Department of Rheumatology, Imperial College, London, UK.
Rheum Dis Clin North Am. 2004 May;30(2):329-47, vii. doi: 10.1016/j.rdc.2004.01.009.
Infliximab was the first anti-TNF agent used to treat rheumatoid arthritis to provide proof of concept of the role of TNF-alpha in this condition. It has become widely used since, principally as an effective treatment in combination with methotrexate, but also as monotherapy for the treatment of Crohn's disease, ankylosing spondylitis,and psoriatic arthritis. The benefits of infliximab in controlling signs and symptoms, improving quality of life, preventing structural joint damage, and possible healing of bone provide an important option for the treatment of rheumatoid arthritis.
英夫利昔单抗是首个用于治疗类风湿关节炎的抗TNF药物,它证实了TNF-α在这种疾病中的作用概念。自那以后,它得到了广泛应用,主要作为与甲氨蝶呤联合使用的有效治疗方法,也作为治疗克罗恩病、强直性脊柱炎和银屑病关节炎的单一疗法。英夫利昔单抗在控制体征和症状、改善生活质量、预防关节结构损伤以及可能促进骨愈合方面的益处,为类风湿关节炎的治疗提供了一个重要选择。